MedPath

Fluoroscopic, Contact Force and Local Impedance With Ultra-high Density Mapping Guided Radiofrequency Ablation Comparison for cavoTricuspid Isthmus dependenT Atrial fluttER: the FLUTTER Study

Not Applicable
Withdrawn
Conditions
Typical Atrial Flutter
Interventions
Device: Contact force guided ablation
Device: Fluoroscopically guided ablation
Device: Local impedance guide ablation
Registration Number
NCT04434599
Lead Sponsor
University of Manchester
Brief Summary

Catheter ablation is a first-line treatment for patients with cavotricuspid isthmus (CTI) dependent atrial flutter (AFL; also known as typical AFL), a common arrhythmia. This is done using radiofrequency (RF) catheters and single-procedure success is approximately 95%. Ablation is often done using one of three methods:

1. fluoroscopically, using X-rays to guide the operator to visualise catheter position within the heart. This method involves the most radiation exposure to patient and operator. Ablation is generally performed for a set time-period (eg. 30-60secs) to ensure each ablation lesion is successful.

2. using a 3-dimensional mapping system which allows the catheters to be magnetically located and visualised on a monitor without X-rays, and using "contact force" (CF) sensing catheters. This requires minimal X-ray use, and by ensuring a minimum degree of force between catheter tip and the heart before applying RF for a set time-period (eg. 30 seconds), operators can be more confident of successful lesions.

3. using an ultra-high density mapping system which uses magnetic tracking as above, but allows higher resolution visualisation of the cardiac electrical system with potential for improving procedure success; this has not yet been formally evaluated for AFL. Catheters using this method use "local impedance" (LI) instead of CF. This is a direct measure of heart tissue impedance with real-time changes during ablation. A minimum drop or plateau in the LI value during ablation allows confidence of lesion success, without the need to ablate for a pre-defined time-period. This could potentially reduce ablation time and subsequent complications, but has also not yet been formally compared to the above for this indication.

This prospective randomised study aims to compare these three standard of care procedures to determine if differences in ablation metrics, efficacy and safety exist.

Detailed Description

Not available

Recruitment & Eligibility

Status
WITHDRAWN
Sex
All
Target Recruitment
Not specified
Inclusion Criteria
  • Patients under the care of the NHS
  • Aged 18-80 years
  • Symptoms and 12-lead ECG suggestive of typical (cavotricuspid isthmus dependent) atrial flutter
  • Due to undergo first-time cavotricuspid isthmus ablation (including as part of a combined ablation if also having pulmonary vein isolation for atrial fibrillation) on clinical grounds
Exclusion Criteria

Pre-procedure:

  • Inability to given informed consent / lack of mental capacity
  • Obesity (BMI >40)
  • Congenital heart disease or tricuspid valve abnormalities likely to prolong procedure time, including Ebstein anomaly, atrial septal defects, tricuspid valve repair or replacement, severe tricuspid valve regurgitation
  • Inability or unwillingness to receive oral anticoagulation with a vitamin K antagonist (VKA) or non-VKA oral anticoagulant (NOAC)
  • Previous cavotricuspid isthmus ablation procedure
  • Known infiltrative cardiomyopathy
  • Pregnancy
  • Age < 18 or >80
  • Inability to speak adequate English/need for an interpreter for study consent process

Post procedure:

  • arrhythmia mechanism found not to be cavotricuspid isthmus dependent atrial flutter

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Contact force guided ablationContact force guided ablationThese patients will receive one catheter ablation of typical atrial flutter by contact force guided radiofrequency ablation catheters using the CARTO 3D electroanatomic mapping system
Fluoroscopically guided ablationFluoroscopically guided ablationThese patients will receive one catheter ablation of typical atrial flutter by fluoroscopically guided radiofrequency ablation catheters
Local impedance guided ablationLocal impedance guide ablationThese patients will receive one catheter ablation of typical atrial flutter by local impedence guided radiofrequency ablation catheters using the Rhythmia Ultra-high density 3D electroanatomic mapping system
Primary Outcome Measures
NameTimeMethod
Time from first application of radiofrequency energy to confirmation of bidirectional cavotricuspid isthmus blockAt time of procedure

Time from first application of radiofrequency energy to confirmation of bidirectional cavotricuspid isthmus block

Secondary Outcome Measures
NameTimeMethod
Mean total number of ablation lesions required to achieve bidirectional cavotricuspid isthmus blockAt time of procedure

Mean total number of ablation lesions required to achieve bidirectional cavotricuspid isthmus block

Number of cases where bidirectional cavotricuspid isthmus block was not achieved after the first pass of ablationAt time of procedure

Number of cases where bidirectional cavotricuspid isthmus block was not achieved after the first pass of ablation

Mean time taken for second pass ablation (with or without the use of 3D mapping) to achieve bidirectional cavotricuspid isthmus blockAt time of procedure

Mean time taken for second pass ablation (with or without the use of 3D mapping) to achieve bidirectional cavotricuspid isthmus block

Mean total ablation time to achieve bidirectional cavotricuspid isthmus blockAt time of procedure

Mean total ablation time to achieve bidirectional cavotricuspid isthmus block

Locations of breakthrough across the initial ablation lineAt time of procedure

Locations of breakthrough across the initial ablation line

Frequency of procedural complicationsAt time of and immediately following procedure

Frequency of procedural complications

Acute and medium-term success rates12 months

Acute and medium-term success rates

Mean total radiation exposureAt time of procedure

Mean total radiation exposure

Ā© Copyright 2025. All Rights Reserved by MedPath